Committee on International Relations U.S. House of Representatives
Henry J. Hyde, Chairman
CONTACT: Sam Stratman, (202) 226-7875, March 16, 2005
For IMMEDIATE Release
Combating Malaria and Tuberculosis
Christopher Smith Schedules Tuesday Hearing on Implementing
Proven Treatment and Eradication Methods
BACKGROUND: The global pandemic of HIV/AIDS is frequently the
focus of high-profile news coverage, but much of the developing
world is being ravaged by two other, relatively unknown, killer
diseases: malaria and tuberculosis (TB). One-third of the world
is infected with the TB bacterium, and it is the leading cause of
death for people with HIV/AIDS. Africa is currently experiencing
a TB explosion due in large part to the AIDS pandemic. Similarly,
Malaria is the primary killer of children and pregnant women in
Africa, and one of the top killers in Asia and South America.
Every day about 3,000 children die from the disease worldwide.
Infection rates for malaria dwarf those of HIV/AIDS, and the vast
majority of malaria patients are pregnant women and children
living in poverty. However, both diseases are preventable and
curable. A six-month course of anti-TB drugs costs only $12 and
can produce cure rates of up to 95 percent even in the poorest
countries. Malaria, likewise, is inexpensive and easy to treat,
and can be controlled with proven successful methods combining
anti-malarial drugs, bed nets, and use of small, environmentally
safe amounts of insecticide in homes and buildings. In FY 2005,
the United States will provide $2.9 billion in bilateral and
multilateral assistance to fight HIV/AIDS, malaria and
tuberculosis. Among the witnesses scheduled to testify Tuesday is
Youssou N?Dour, Senegalese Jazz Musician, Goodwill Ambassador,
and Roll Back Malaria Partnership.
WHAT: Subcommittee Oversight Hearing: Malaria and TB:
Implementing Proven Treatment
and Eradication Methods
Subcommittee on Africa, Global Human Rights and International Operations,
U.S. Rep. Christopher H. Smith (R-NJ), Chairman
WHEN: 2:00 p.m., Tuesday, April 26, 2005
WHERE: Room 2172 Rayburn House Office Building
WITNESSES: Mark Dybul, M.D., Assistant U.S. Global AIDS
Coordinator and Chief Medical Officer, Office of the
U.S. Global AIDS Coordinator, U.S. Department of State;
Michael Miller, Deputy Assistant Administrator, Bureau for Global
Health, U.S. Agency for
International Development;
William Moeller, President and CEO, American Biotech Labs;
Youssou N?Dour, Senegalese Jazz Musician, Goodwill Ambassador,
Roll Back Malaria Partnership; and
Paul Nunn, M.D., Coordinator, TB, HIV, and Drug Resistance Unit,
World Health Organization.
http://wwwc.house.gov/international_relations/109/news042605 .htm
Written Testimony of William D. Moeller
President, American Biotech Laboratories
80 West Canyon Crest Road
Alpine, Utah 84004
Presented to Members of The House International Relations Committee
Subcommittee on Africa, Global Human Rights, and International Operations
April 26, 2005
INTRODUCTION
Good Morning. I am William D. Moeller, Chairman and President of
American Biotech Laboratories
of Alpine, Utah ("ABL"), a company which produces engineered,
metallic silver, nano-sized particles
in water-based products. Our engineered silver particles have
performed far beyond anyone's
expectations as anti-microbial agents, against a staggering
variety of microbes such as malaria, flesheating
bacteria (MRSA - Methicillin Resistant Staphylococcus aureus) and E.coli.
Whether used on surfaces as disinfectants or if taken internally
as supplements, all of our ABL products
are non-toxic and have no known adverse human side effects. Our
products have surprised many
experts in the medical and science worlds because of their
ability to combat bacteria, yeast, and viruses.
ABL products have been proven to destroy anthrax spores and
bubonic plague bacteria on surfaces, to
eliminate the malaria parasite in humans and a host of other
beneficial results.
We have developed five products to date as well as several other
new products currently in our product
development pipeline. We manufacture all of our products in the
United States. One product ASAPAGX-
32 (a water solution containing 32 ppm of our engineered silver
nano-particles) has already been
approved by the EPA as a surface disinfectant for hard,
non-porous surfaces in commercial, residential,
industrial, hospital and medical environments. Another product
called Silgel is a non-toxic
moisturizing gel, which utilizes our ASAP-AGX-32 as a raw
material supply of silver particles. It is
currently undergoing the final steps for FDA approval for the
treatment of lacerations, first and second
degree burns, abrasions, surgical wounds, skin ulcers etc.
Several other new ABL products will soon
warrant the filing of new FDA and/or USDA applications.
More.....
http://wwwc.house.gov/international_relations/109/moe042605. pdf
--
The Silver List is a moderated forum for discussing Colloidal Silver.
Instructions for unsubscribing are posted at: http://silverlist.org
To post, address your message to: silver-list@eskimo.com
Silver List archive: http://escribe.com/health/thesilverlist/index.html
Address Off-Topic messages to: silver-off-topic-l...@eskimo.com
OT Archive: http://escribe.com/health/silverofftopiclist/index.html
List maintainer: Mike Devour <mdev...@eskimo.com>
